Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

MASH, which was previously known as non–alcohol related steatohepatitis (NASH), is often asymptomatic or leads to nonspecific symptoms, making progression to more severe stages of liver disease ...

But one risk you may not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH). MASH is a type of liver inflammation and damage caused by a buildup of fat in the liver.

Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week data from a mid-stage study of its lead product candidate, efruxifermin ...

in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH). Among patients with baseline and week 96 biopsies ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in ...

Obesity and diabetes are the leading causes of metabolic dysfunction-associated steatohepatitis ... such as severity of liver disease at their baseline liver biopsy. Fifteen years after enrollment ...

0000000000000323 3. Huang DQ, Wilson LA, Behling C, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes ...

Traditionally, the liver biopsy has played a key role in the ... the presence of confounding patterns of injury (such as steatohepatitis coexisting with chronic viral hepatitis), and the presence ...